Amanda Bruno BS, MPH, PhD

Amanda Bruno, PhD, has 17 years experience in defining and examining value in healthcare. As the Head, Value Evidence & Outcomes, Oncology at GSK, she has led the evidence generation strategy for several immune-oncology, epigenetic and cell & gene therapies. Prior to GSK, Dr Bruno led the US Specialty health economics and outcomes research (HEOR) team at Bristol-Myers Squibb and worked in the field as the portfolio medical lead for US national and regional health plans. During this time, she led an engagement with a large national payer to conduct a real world study that resulted in positive reimbursement negotiation for a marketed product.

Before joining industry, Dr Bruno was a Senior Director in Scientific Consulting at Xcenda—a consultancy owned by Amerisource Bergen Corporation. In this role, she specialized in scientific and commercial activities to demonstrate product value and drive market access for several large, mid-size and small pharmaceutical and biotech companies.
Before Xcenda, Dr Bruno was responsible for leading a health services research team that supported industry and managed care for a consultancy in Los Angeles that is now part of IMS Health. In this role, she led the development of a proprietary physician cost of care model that accounted for 25 percent more variation in patient costs and linked physician quality to cost measurement. She also led a multi-year prospective study for a leading respiratory medicine as well as a set of utilization and safety studies based on linked proprietary databases for solid organ transplant recipients.